Differential effects of enalapril-felodipine versus enalapril-lercanidipine combination drug treatment on sympathetic nerve traffic and metabolic profile in obesity-related hypertension

Gino Seravalle, Gianmaria Brambilla, Daniela Prata Pizzalla, Anna Casati, Marta Riva, Cesare Cuspidi, Michele Bombelli, Giuseppe Mancia, Guido Grassi

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Scanty information is available on the effects of combination drug treatment based on an ACE inhibitor and a calcium channel blocker on the neurometabolic alterations characterizing obesity-related hypertension (OHT). After 2-week run-in with enalapril (20 mg), 36 OHTs were randomized according to a double-blind crossover design to a combination therapy with either lercanidipine 10 mg (L) or felodipine extended release 5 mg (F), each lasting 8 weeks. Measurements included clinic and ambulatory blood pressure (BP) and heart rate, homeostasis model assessment index, plasma norepinephrine, and muscle sympathetic nerve activity. Patients with uncontrolled BP were then uptitrated to 20 mg/d (L) and 10 mg/d (F) combined with enalapril 20 mg, respectively, for further 8 weeks. For similar BP reductions, enalapril-lercanidipine (EL) caused norepinephrine and MSNA increases significantly less pronounced than those seen with enalapril-felodipine, the lesser sympathoexcitation observed with EL being coupled with a significant improvement in homeostasis model assessment index. This was the case also when L and F were uptitrated in the combination. In OHT, at variance from enalapril-felodipine, EL combination is almost entirely devoid of any major sympathoexcitatory effect and is associated with an improvement in insulin sensitivity.

Original languageEnglish
Pages (from-to)244-251
Number of pages8
JournalJournal of the American Society of Hypertension
Volume10
Issue number3
DOIs
Publication statusPublished - Mar 1 2016

Fingerprint

Felodipine
Enalapril
Metabolome
Drug Combinations
Obesity
Hypertension
Blood Pressure
Therapeutics
Norepinephrine
Homeostasis
Calcium Channel Blockers
lercanidipine
Angiotensin-Converting Enzyme Inhibitors
Cross-Over Studies
Insulin Resistance
Heart Rate
Muscles

Keywords

  • Combination drug treatment
  • lercanidipine
  • obesity-related hypertension
  • sympathetic activity

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Internal Medicine

Cite this

Differential effects of enalapril-felodipine versus enalapril-lercanidipine combination drug treatment on sympathetic nerve traffic and metabolic profile in obesity-related hypertension. / Seravalle, Gino; Brambilla, Gianmaria; Pizzalla, Daniela Prata; Casati, Anna; Riva, Marta; Cuspidi, Cesare; Bombelli, Michele; Mancia, Giuseppe; Grassi, Guido.

In: Journal of the American Society of Hypertension, Vol. 10, No. 3, 01.03.2016, p. 244-251.

Research output: Contribution to journalArticle

@article{0a3f23fce70940768ee704a5c9e9a689,
title = "Differential effects of enalapril-felodipine versus enalapril-lercanidipine combination drug treatment on sympathetic nerve traffic and metabolic profile in obesity-related hypertension",
abstract = "Scanty information is available on the effects of combination drug treatment based on an ACE inhibitor and a calcium channel blocker on the neurometabolic alterations characterizing obesity-related hypertension (OHT). After 2-week run-in with enalapril (20 mg), 36 OHTs were randomized according to a double-blind crossover design to a combination therapy with either lercanidipine 10 mg (L) or felodipine extended release 5 mg (F), each lasting 8 weeks. Measurements included clinic and ambulatory blood pressure (BP) and heart rate, homeostasis model assessment index, plasma norepinephrine, and muscle sympathetic nerve activity. Patients with uncontrolled BP were then uptitrated to 20 mg/d (L) and 10 mg/d (F) combined with enalapril 20 mg, respectively, for further 8 weeks. For similar BP reductions, enalapril-lercanidipine (EL) caused norepinephrine and MSNA increases significantly less pronounced than those seen with enalapril-felodipine, the lesser sympathoexcitation observed with EL being coupled with a significant improvement in homeostasis model assessment index. This was the case also when L and F were uptitrated in the combination. In OHT, at variance from enalapril-felodipine, EL combination is almost entirely devoid of any major sympathoexcitatory effect and is associated with an improvement in insulin sensitivity.",
keywords = "Combination drug treatment, lercanidipine, obesity-related hypertension, sympathetic activity",
author = "Gino Seravalle and Gianmaria Brambilla and Pizzalla, {Daniela Prata} and Anna Casati and Marta Riva and Cesare Cuspidi and Michele Bombelli and Giuseppe Mancia and Guido Grassi",
year = "2016",
month = "3",
day = "1",
doi = "10.1016/j.jash.2016.01.006",
language = "English",
volume = "10",
pages = "244--251",
journal = "Journal of the American Society of Hypertension",
issn = "1933-1711",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Differential effects of enalapril-felodipine versus enalapril-lercanidipine combination drug treatment on sympathetic nerve traffic and metabolic profile in obesity-related hypertension

AU - Seravalle, Gino

AU - Brambilla, Gianmaria

AU - Pizzalla, Daniela Prata

AU - Casati, Anna

AU - Riva, Marta

AU - Cuspidi, Cesare

AU - Bombelli, Michele

AU - Mancia, Giuseppe

AU - Grassi, Guido

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Scanty information is available on the effects of combination drug treatment based on an ACE inhibitor and a calcium channel blocker on the neurometabolic alterations characterizing obesity-related hypertension (OHT). After 2-week run-in with enalapril (20 mg), 36 OHTs were randomized according to a double-blind crossover design to a combination therapy with either lercanidipine 10 mg (L) or felodipine extended release 5 mg (F), each lasting 8 weeks. Measurements included clinic and ambulatory blood pressure (BP) and heart rate, homeostasis model assessment index, plasma norepinephrine, and muscle sympathetic nerve activity. Patients with uncontrolled BP were then uptitrated to 20 mg/d (L) and 10 mg/d (F) combined with enalapril 20 mg, respectively, for further 8 weeks. For similar BP reductions, enalapril-lercanidipine (EL) caused norepinephrine and MSNA increases significantly less pronounced than those seen with enalapril-felodipine, the lesser sympathoexcitation observed with EL being coupled with a significant improvement in homeostasis model assessment index. This was the case also when L and F were uptitrated in the combination. In OHT, at variance from enalapril-felodipine, EL combination is almost entirely devoid of any major sympathoexcitatory effect and is associated with an improvement in insulin sensitivity.

AB - Scanty information is available on the effects of combination drug treatment based on an ACE inhibitor and a calcium channel blocker on the neurometabolic alterations characterizing obesity-related hypertension (OHT). After 2-week run-in with enalapril (20 mg), 36 OHTs were randomized according to a double-blind crossover design to a combination therapy with either lercanidipine 10 mg (L) or felodipine extended release 5 mg (F), each lasting 8 weeks. Measurements included clinic and ambulatory blood pressure (BP) and heart rate, homeostasis model assessment index, plasma norepinephrine, and muscle sympathetic nerve activity. Patients with uncontrolled BP were then uptitrated to 20 mg/d (L) and 10 mg/d (F) combined with enalapril 20 mg, respectively, for further 8 weeks. For similar BP reductions, enalapril-lercanidipine (EL) caused norepinephrine and MSNA increases significantly less pronounced than those seen with enalapril-felodipine, the lesser sympathoexcitation observed with EL being coupled with a significant improvement in homeostasis model assessment index. This was the case also when L and F were uptitrated in the combination. In OHT, at variance from enalapril-felodipine, EL combination is almost entirely devoid of any major sympathoexcitatory effect and is associated with an improvement in insulin sensitivity.

KW - Combination drug treatment

KW - lercanidipine

KW - obesity-related hypertension

KW - sympathetic activity

UR - http://www.scopus.com/inward/record.url?scp=84960320408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960320408&partnerID=8YFLogxK

U2 - 10.1016/j.jash.2016.01.006

DO - 10.1016/j.jash.2016.01.006

M3 - Article

AN - SCOPUS:84960320408

VL - 10

SP - 244

EP - 251

JO - Journal of the American Society of Hypertension

JF - Journal of the American Society of Hypertension

SN - 1933-1711

IS - 3

ER -